Core Viewpoint - Skyworth Group has announced a dual plan for privatization and the spin-off of its solar business, aiming to provide shareholders with a combination of cash and high-growth equity, while also signaling a strategic shift from traditional home appliances to renewable energy [2][3]. Summary by Sections Privatization and Spin-off Plan - The plan involves two main steps: first, Skyworth intends to independently list its solar business on the Hong Kong Stock Exchange, distributing shares to existing shareholders at a ratio of approximately 0.37 shares of solar business for each Skyworth share held, with a theoretical value of about HKD 6.13 per share [3][6]. - Simultaneously, the company will implement privatization, offering shareholders a choice between receiving HKD 4.03 in cash or one share of the newly privatized company [3][5]. Shareholder Returns - Shareholders opting for the cash option will receive a total return of approximately HKD 10.16, representing a premium of 96.15% over the last closing price of HKD 5.18 prior to the announcement [5][6]. Business Transition - The move reflects the necessity for traditional home appliance businesses to adapt amid pressures from declining demand and increased competition, with Skyworth's smart home appliance revenue facing growth limitations [9][11]. - The solar business has emerged as a key growth driver, with revenue from this segment reaching HKD 138.36 billion in the first half of 2025, a significant increase of 53.5% year-on-year, and accounting for over 38% of total revenue [11][13]. Future Strategic Plans - The spin-off of the solar business is seen as the first step in a broader strategy, with plans to eventually list other segments such as energy storage and automotive electronics, aiming to create a renewable energy industry cluster [13].

文章来源：PV光圈见闻公众号 创维集团公布， 于1月4日董事会议决分派及创维光伏上市及股份回购计划。 股份回购计划生效后， 公司将向联交所申请撤销上市地位，公司将向全体股东(包括控股股东黄氏一致行动集团)分派所持有的创维光伏股份。 创维光伏将以介绍方式申请在香港联交所主板上市。公司将通过股份回购计划撤销上市地位，当中涉及注销计划股份，以换取 现金选择，即每股计划股 份兑换4.03港元的现金，或股份选择，即每股计划股份兑换一股新股份。 分派、创维光伏上市及股份回购计划的完成互为条件，且分派、创维光伏上市及股份回购计划将于同日或大致于同日发生。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責,對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (5) 股 份 恢 復 買 賣 本公司之獨家財務顧問 4 中信证券 本公告僅供參考,並不構成收購、購買或認購本公司或創維光伏證券之邀請或要 約,亦非在任何司法管轄區招攬任何投票權或批准。 本公告不會在 構成 建反 任 何 司法 管 轄 區 相 關 法 律 的 情 況 ...

Group 1 - The core announcement from Skyworth Group includes plans to spin off Skyworth Photovoltaic for independent listing, advance the group's privatization and delisting, and initiate a share buyback program [1] - Following the announcement, Skyworth's stock opened over 42% higher, reaching a peak increase of 42.66%, with a trading volume of 8.11 million HKD [1] - Skyworth Photovoltaic aims to become a global leader in distributed energy products and services, focusing on photovoltaic power station system integration, R&D design, smart manufacturing, and energy management [3] Group 2 - Financially, Skyworth Group has sufficient funds to support its plans, with approximately 635 million shares issued, and a potential cash payout of up to 25.57 billion HKD if all shareholders opt for cash compensation [3] - Revenue and net profit projections for Skyworth Photovoltaic from 2022 to 2025 show significant growth, with revenues of 11.93 billion, 23.22 billion, 20.15 billion, and 13.78 billion HKD, and net profits of 0.36 billion, 0.87 billion, 0.79 billion, and 0.53 billion HKD respectively [3] - The traditional home appliance business of Skyworth is experiencing slow growth, while Skyworth Photovoltaic is identified as the main growth engine for revenue and profit, with independent listing expected to unlock its growth potential and broaden financing channels [3]

Group 1 - The core announcement is that Nanjing Dazhong Numerical Control Technology Co., Ltd. (referred to as Dazhong Numerical Control) plans to go public in Hong Kong, with a shareholder meeting scheduled for May 12, 2026, to review the proposal [1] - Dazhong Technology aims to accelerate its expansion into the mainland market, attract and incentivize professional talent, and enhance global competitiveness through this public offering [1] - The proposed issuance of new shares is expected to account for approximately 25% of the total share capital after the issuance, with the company retaining about 75% ownership [1] Group 2 - Dazhong Technology was established in 1980 and is headquartered in Taoyuan City, Taiwan, specializing in the manufacturing of PCB equipment and CNC milling machines [2] - The company provides specialized machinery for PCB forming, drilling, thin plate cutting, and glass panel processing, and has developed a comprehensive operational system including design, manufacturing, quality control, sales, and financial management [2]

Group 1 - The core announcement is that Dazhong Technology Co., Ltd. plans to list its subsidiary, Dazhong CNC Technology Co., Ltd., on the Hong Kong Stock Exchange by May 12, 2026, to enhance market expansion and global competitiveness [1] - The proposed new shares will account for approximately 25% of the total share capital after issuance, with Dazhong Technology retaining about 75% ownership [1] - The company emphasizes that the spin-off listing will comply with relevant regulations and will not affect existing shareholder rights or its listing status in Taiwan [1] Group 2 - Dazhong Technology was established in 1980 and is headquartered in Taoyuan City, Taiwan, specializing in the manufacturing of PCB equipment and CNC milling machines [2] - The company has developed a comprehensive operational system that includes mechanical design, manufacturing assembly, quality inspection, sales service, and financial management [2] - Dazhong Technology aims to provide customers with the most complete equipment and sustainable services [2]

Core Viewpoint - Xiansheng Pharmaceutical's subsidiary, Xiansheng Zaiming, has submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for research and development, team expansion, and business growth [2][4]. Group 1: Company Overview - Xiansheng Zaiming focuses on the research, development, and commercialization of innovative oncology drugs, having been established in December 2020 [4]. - The company has five commercialized products, including anti-angiogenesis drug Endu and PD-(L)1 inhibitor Envida, with over 15 products in its research pipeline [4]. Group 2: Financial Performance - Xiansheng Zaiming reported revenues of 1.522 billion yuan, 1.296 billion yuan, and 1.238 billion yuan for the first three quarters of 2023, 2024, and 2025, respectively, while incurring losses of 336 million yuan, 506 million yuan, and 303 million yuan during the same periods [4]. - Research and development expenses for the same periods were 831 million yuan, 708 million yuan, and 512 million yuan, with sales expenses of 626 million yuan, 629 million yuan, and 532 million yuan [5]. Group 3: Strategic Initiatives - The company aims to enhance financial flexibility and optimize cash flow through its independent listing, allowing both Xiansheng Pharmaceutical and Xiansheng Zaiming to access separate capital markets [4]. - Xiansheng Zaiming has entered into a global licensing agreement with Ipsen for the ADC SIM0613, potentially earning up to 1.06 billion USD in total payments, including milestone payments and royalties [6].

Core Viewpoint - The company, Xiansheng Zaiming Pharmaceutical Co., Ltd., has submitted an IPO application to the Hong Kong Stock Exchange, aiming to establish a dedicated financing platform for its oncology business, which is currently under the parent company, Xiansheng Pharmaceutical [1][8]. Financial Performance - The company reported revenues of 1.522 billion yuan, 1.296 billion yuan, and 1.238 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively [2]. - Despite stable revenue growth, the company remains in a loss position due to high R&D and sales expenses, recording net losses of 336 million yuan, 506 million yuan, and 303 million yuan for the same periods [6]. - R&D costs were 831 million yuan, 708 million yuan, and 512 million yuan for 2023, 2024, and the first nine months of 2025, with R&D expenses exceeding 50% of revenue in 2023 and 2024 [5]. Business Strategy - The company focuses on the development and commercialization of innovative oncology drugs, having five commercialized products that contribute over 90% of total revenue [4]. - The split from Xiansheng Pharmaceutical allows the company to optimize its financial structure while maintaining absolute control over the oncology business [2]. - The company has established a sales and marketing team of over 1,200 people to enhance product marketization [5]. Market Position and Collaborations - Xiansheng Zaiming has engaged in multiple licensing collaborations with companies like AbbVie, Ipsen, and NextCure, with a potential total transaction value exceeding 2.8 billion USD [5]. - The company ranks first in the number of oncology asset transactions and fourth in total value among Chinese biopharmaceutical companies [5]. Challenges and Considerations - The company faces challenges related to high market channel concentration, with the top five customers accounting for over 65% of revenue [11]. - The overall gross margin has decreased from approximately 72% to 68.1%, attributed to structural adjustments in revenue sources and product mix [12]. - The company has set a timeline for its IPO process, needing to submit its application by June 2027 and complete the listing by the end of 2028, with penalties for delays [12].

Market Overview - The Hang Seng Index fell by 0.55%, down 149 points, closing at 26,850 points, while the Hang Seng Tech Index dropped by 1.83% [1] - The trading volume in the Hong Kong stock market reached HKD 163.9 billion in the morning session [1] Company Highlights - Jiexin International Resources (03858) rose over 5%, reaching a new high as black tungsten ore prices surpassed 500,000 yuan, prompting several tungsten companies to raise long-term contract prices [1] - Likin Resources (02245) increased by over 10% due to disruptions in Indonesian nickel ore quotas, while Zhongwei New Materials (02579) gained over 9% [1] - China Rare Earth Holdings (03788) experienced significant volatility, rising by 8% after announcing the termination of its spin-off listing plan and plans to rename itself "Rare Earth Gold" [1] - Ocean Park Hong Kong (02255) surged over 10%, with visitor numbers on the first day of the New Year holiday increasing by 60% year-on-year [1] - Zhipu (02513) rose over 4% after announcing a collaboration with Huawei to open-source a new generation image generation model [1] - China Heartland Fertilizer (01866) increased by over 4%, anticipating a potential global urea supply shortage, and has been actively repurchasing shares [1] - Woan Robotics (06600) gained over 7% following the release of its humanoid intelligent robot, Onero [1] - Jiantao Laminates (01888) saw a nearly 6% increase after announcing a price hike, which is expected to become a trend in the copper-clad laminate industry [1] - Qiu Tai Technology (01478) declined over 7% as Citigroup reported that the company's net profit last year fell below expectations [1] Other Notable Movements - Kanglong Chemical (03759) dropped over 5% after announcing a placement of shares at an 8.5% discount, aiming to raise nearly HKD 1.32 billion [2] - Trip.com Group (09961) plummeted over 19% due to an investigation by the State Administration for Market Regulation for alleged monopoly practices, while Same City Travel (00780) fell over 11% [2]

Core Viewpoint - Baidu's subsidiary Kunlun Chip has submitted an A1 listing application to the Hong Kong Stock Exchange, signaling a potential shift in strategy towards valuing its core assets through spin-offs [1][2]. Group 1: Spin-off Significance - The spin-off of Kunlun Chip is not just a subsidiary listing but a signal of Baidu's intent to unlock value amid a challenging environment for Chinese internet giants regarding asset separation [2]. - The market has historically undervalued Baidu, perceiving it primarily as a traditional search advertising company, despite its significant investments in AI and technology [3][4]. - Kunlun Chip, as a leading AI chip manufacturer, has been undervalued within Baidu, which limits its growth potential and financing capabilities [5][6]. Group 2: Market Dynamics and Identity - The chip industry operates on a principle of neutrality, which has hindered Kunlun Chip's growth while it remained a part of Baidu [7]. - By becoming an independent entity, Kunlun Chip can attract a broader customer base and tap into a larger total addressable market (TAM) [7]. - The financial burden of funding chip development through Baidu's advertising revenue is no longer sustainable, making the spin-off a strategic move to optimize cash flow [8]. Group 3: Future Speculations on Autonomous Driving - The potential for Baidu to spin off its autonomous driving business, particularly the Apollo project, is being speculated as the next logical step following Kunlun Chip's separation [9][10]. - The autonomous driving sector is at a critical juncture, with the need for significant investment to scale operations, which could negatively impact Baidu's financial performance if retained within the company [10][11]. - A proposed spin-off could involve creating a new company focused solely on autonomous driving, allowing for better valuation and attracting strategic investors [11][12]. Group 4: Strategic Implications - The spin-off of Kunlun Chip may serve as a precursor to further separations within Baidu, allowing each business unit to thrive independently [14][15]. - The historical context of successful spin-offs in the tech industry suggests that separating high-growth potential businesses can lead to enhanced valuations and operational efficiencies [13][14]. - Baidu's actions indicate a shift from maintaining a large conglomerate to enabling individual units with unique growth trajectories to compete effectively in their respective markets [15].

Group 1 - The core point of the article is that Jollibee Foods Corporation plans to spin off its international operations, including its Chinese business, into a new entity called "Jollibee International Company," with plans for an independent listing on a U.S. stock exchange by the end of 2027 [2][3] - The spin-off aims to allow the original Jollibee Group to focus on its stable and cash-generating domestic market in the Philippines, while the new entity will pursue global expansion ambitions [2] - The Chinese operations, which include brands like Yonghe King and Hongzhuangyuan with over 550 stores, are facing intense competition from local brands such as Luckin Coffee and Mixue Ice Cream, prompting strategic adjustments [2] Group 2 - Yonghe King has implemented a "value model" by lowering menu prices to attract customers, resulting in a significant increase in order volume [2] - The company has also reduced the costs of opening new stores and plans to focus on second-tier cities with more favorable rental conditions, aiming to shorten the investment payback period [2] - As a result of these strategies, Jollibee's Chinese business saw a same-store sales growth of 8% in the third quarter of 2025 [2] Group 3 - The spin-off is seen as a "shot in the arm" for Jollibee's international business, particularly in China, as it will allow for more focused funding for international expansion and enhance brand visibility in global markets [3] - This move will enable Chinese brands like Yonghe King to potentially receive more resources to accelerate their transformation and expansion in the Chinese market [3] - The success of the planned U.S. listing will depend on market conditions and regulatory approvals, but it sets the stage for a promising future for the Chinese fast-food business [3]